为全面贯彻党的二十大精神，落实国家创新驱动发展战略，推动医工结合科技创新和成 果转化高质量发展，加速推进"健康中国"建设。 2026年1月18日， " 汇智·无界"2026第 三届全球健康产业创新大会将在北京中关村国际创新中心 隆重举办。 敬请期待！ 【导读】 在人工智能、大数据等颠覆性技术的驱动下，全球健康产业正以前所未有的速度和广度 重塑其发展范式。从精准诊断到智能诊疗，从创新药物研发到全生命周期健康管理，数 智化浪潮正在打破传统医疗的边界，为应对全球公共卫生挑战、提升全民健康水平提供 了全新的解决方案。 本届大会将邀请相关部委同志、两院院士、国内外知名专家学者、高校、科研机构和临 床医院专家、企业代表等齐聚一堂，共同开启一场关于健康产业未来的无界对话，携手 绘制数智时代人类健康的崭新蓝图。 汇聚智慧、打破边界、创造未来！ 大会主论坛嘉宾 首都医科大学附属北京天坛医院院长 王振常 中国工程院院士 影像医学专家 黄天荫 清华大学副教务长、医学院院长 美国国家医学院外籍院士、新加坡国家科学院院士 赵继宗 中国科学院院士 神经外科专家 金勤献 国家昌平实验室副主任 王兴鹏 应急总医院党委副书记、院长 国家应急医 ...

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 证券代码：300760 证券简称：迈瑞医疗 编号：2025-008 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 路演活动 | | 活动类别 | 现场参观 | | | 其他 电话会议、券商策略会等 | | 参与单位名 | | | 称及人员姓 | 家机构 名参与人员，详见附件清单。 204 484 | | 名 | | | | 年 月 日、11 月 日、11 月 日、11 月 日、11 月 2025 10 31 4-7 10-14 17-21 | | 时间 | 月 月 月 月 日、 24-28 日、12 1-5 日、12 9-11 日、12 16-19 日、12 22-26 | | | 月 日 12 29-31 | | | 深圳市南山区高新技术产业园区科技南十二路迈瑞大厦 | | 地点 | 投资人办公室、券商策略会会场 | | 上市公司接 | 董事会秘书 李文楣 | | 待人员姓名 | 投资者关系团队 ...

双方将以AI+数据为核心驱动力，通过"四大平台+一大体系"建设优化医疗服务，延伸服务半径，推动 资源共享，赋能精细管理，释放数据价值，把西安交大一附院打造成为国内智慧医院新标杆；组建跨学 科科研团队，聚焦临床前沿领域攻坚医工医信融合课题、加速产研转化，依托新技术探索医疗、康养、 教育多元创新服务。 东软集团相关负责人表示，公司与西安交大一附院的全面战略合作，是双方能力的深度融合与价值的倍 增释放，将有力推动医疗健康产业从信息化、数字化、智慧化向数智化加速发展，助力提升我国医疗健 康服务整体质量、效率与可及性，惠及广大民众。 中证报中证网讯(记者宋维东)中国证券报记者12月31日从东软集团（600718）获悉，东软集团日前与西 安交大一附院签署战略合作协议。双方将围绕智慧医院、医工结合、医疗健康产业创新等开启多维度、 多层次的全面战略合作。这是双方20余年稳定、互信合作中的又一里程碑式成果，实现从业务领域协同 向共创、共生、共担战略共同体演进，为数智驱动医院高质量发展再树行业新典范。 东软集团与西安交大一附院合作自2000年延续至今，跨越了中国医疗信息化从起步到高速发展的整个周 期。东软集团全程助力西安交大一附 ...

家住中泰街道的高血压患者王阿姨，近期发现常用的"安诊儿"里多了个特殊的数字管家"余小 康"。"我患高血压好几年了，以前拿到体检报告，看着密密麻麻的指标一头雾水，不知道病情控制得怎 样。"王阿姨笑着说，"现在，'余小康'能针对慢病给我健康建议。我平时有什么问题，也能直接问它， 很方便！" 这位数字管家从何而来？12月21日，国家人工智能应用中试基地（医疗）·浙江年度成果发布分会 场在杭州举行。现场，余杭区卫生健康局分享了"安诊儿"的基层服务新模式。其中让人眼前一亮的是， 通过在"安诊儿"嵌入专职慢病医生智能体"余小康"，慢病患者有了可靠的数字健康工具。 作为浙江省打造的全国首个省域共享、数实融合的医疗健康大模型，"安诊儿"能提供健康咨询、报 告解读、就医陪诊等智慧化服务。而余杭区在积极推广"安诊儿"的基础上，结合自身慢病管理经验，深 度参与到内嵌医生智能体"余小康"的开发过程。 "我们组织区里优秀医生梳理慢病认识、预防、治疗、管理等方面的科普知识和专业要点，凝练老 百姓更易理解的话术体系，让'余小康'有面向慢病患者的智能问答能力。在解读检查报告时，它能针对 性分析慢病相关指征。"余杭区卫生健康局相关负责人介绍， ...

"期待与全国各地，尤其是大湾区的医疗器械企业携手，共同把握机遇助推产业发展。"成都高新区生物 产业局相关负责人在专题产业生态推介中表示，近年来，成都高新区瞄准医药健康领域，始终致力于构 建"人无我有、人有我优"的专项支持政策及覆盖产业发展全生命周期的服务体系。 今年3月，成都高新区正式发布《医药健康产业建圈强链发展政策》（修订），支持力度处于全国领先 梯队。例如，在医疗器械领域，对自主研发或新引进的二类、三类医疗器械品种，单品种最高支持1500 万元，企业累计可获得3000万元奖励。 今年5月，成都高新区又在全国率先发布了医药健康产业"梧桐计划"，这是一份覆盖企业"研发-注册-生 产-上市-出海"全生命周期的102项专业服务清单。它精准对接了企业在研发孵化、临床转化、融资对 接、生产制造等环节的共性需求，致力于为企业提供"低风险、高效率"的创新土壤。 清单包含了总额共计8.6亿元的18项关键采购需求，旨在为高端医疗器械的本地化生产吸引并提供高质 量的配套支持，夯实产业链基础。这些需求精准覆盖机加件、生物类原料、液路和光学件、PCBA（印 制电路板组件）、钣金件等医疗器械生产制造的关键环节，为上游供应商提供了明 ...

Core Viewpoint - Omron Health Medical showcased multiple innovative products at the 8th China International Import Expo, emphasizing the theme "Smart Health for a Better Future" [1] Product Innovations - The company launched the new generation smart blood pressure monitor X1 series, which can sync measurement data with the OMRON plus app to generate trend charts and health reports [1] - The A866T blood pressure monitor features functions such as blood pressure risk grading, intelligent voice broadcasting, app risk analysis, and data sharing, providing a comprehensive health management solution [1] - The W8 nebulizer is designed to be compact and portable, suitable for various scenarios including home, office, travel, and outdoor use [1]

Core Insights - The company reported a revenue of 9.091 billion RMB for Q3 2025, marking a year-on-year increase of 1.53% and a quarter-on-quarter growth of 6.88% [1] - Net profit attributable to shareholders was 2.501 billion RMB, a decrease of 18.69% year-on-year but an increase of 2.50% quarter-on-quarter [1] - Operating cash flow reached 3.351 billion RMB, reflecting a year-on-year growth of 30.02% [1] - The company’s contract liabilities stood at 2.263 billion RMB, up 31.45% year-on-year, indicating strong future revenue support [1] Financial Performance - For the first three quarters of 2025, total revenue was 25.834 billion RMB, with net profit at 7.570 billion RMB [1] - The company approved a cash dividend of 13.50 RMB per 10 shares, totaling 1.637 billion RMB, bringing cumulative dividends to 37.336 billion RMB, six times the IPO fundraising amount [2] International Market Growth - International business grew by 11.93% in Q3, with significant contributions from the European market, which saw over 20% growth [3][4] - The international revenue share for the life information and support segment reached 70%, while the medical imaging segment saw 61% and the in vitro diagnostics segment reached 37% [3] R&D and Innovation - The company invested 2.686 billion RMB in R&D in the first three quarters of 2025, accounting for 10.40% of total revenue [5] - A total of 12,513 patents have been applied for, with 6,355 patents granted, including 3,246 invention patents [5] - New product launches in Q3 included advanced diagnostic kits and medical systems, enhancing the product portfolio [6] Strategic Direction - The company is focusing on building a global supply chain and localized production to support long-term international growth [5] - The establishment of a smart medical ecosystem integrating "equipment + IT + AI" is underway, with ongoing development of intelligent applications in various medical fields [7] - The company aims to enhance its global presence and customer engagement through a diversified product matrix and high-quality ecosystem [8]

Core Insights - The company reported a revenue of 9.091 billion yuan for Q3 2025, marking a year-on-year increase of 1.53% and a quarter-on-quarter increase of 6.88% [1] - The net profit attributable to shareholders for Q3 2025 was 2.501 billion yuan, a year-on-year decrease of 18.69% but a quarter-on-quarter increase of 2.50% [1] - Operating cash flow reached 3.351 billion yuan, reflecting a year-on-year growth of 30.02% [1] Revenue Breakdown - The international business grew by 11.93% year-on-year in Q3 2025, with significant performance in the European market, which saw over 20% growth [2] - The life information and support segment generated 2.952 billion yuan in revenue, up 2.60% year-on-year, with minimally invasive surgery business growing over 25% [2] - The medical imaging segment's revenue was 1.689 billion yuan, remaining stable year-on-year, while international medical imaging saw high single-digit growth [2] - The in-vitro diagnostics segment achieved 3.634 billion yuan in revenue, with international in-vitro diagnostics growing at double-digit rates [2] R&D Investment - The company invests approximately 10% of its revenue in R&D, with Q3 2025 R&D expenditure reaching 2.686 billion yuan, accounting for 10.40% of revenue [3] - As of September 30, 2025, the company has filed 12,513 patents, including 9,034 invention patents, with 6,355 patents granted [3] Product Innovation - The company launched several new products in Q3 2025, including high-sensitivity cardiac troponin T assay kits and D-dimer assay kits in the in-vitro diagnostics segment [4] - In the life information and support field, new products include perioperative decision support systems and advanced anesthesia systems [4] - The medical imaging sector introduced the multifunctional intraoperative visualization ultrasound system [4] Strategic Direction - The company is advancing towards high-end and intelligent solutions, establishing a digital healthcare ecosystem that integrates "equipment + IT + AI" [5] - The global medical device market is expanding, and the company aims to enhance its innovative capabilities while focusing on internationalization and local platform development [5] - The company is committed to contributing comprehensive solutions to global clients through a diverse product matrix and high-quality ecosystem [5]

Core Insights - The company reported a revenue of 9.091 billion RMB for Q3 2025, marking a year-on-year increase of 1.53% and a quarter-on-quarter increase of 6.88% [1] - Net profit attributable to shareholders was 2.501 billion RMB, a year-on-year decrease of 18.69% but a quarter-on-quarter increase of 2.50% [1] - Operating cash flow reached 3.351 billion RMB, reflecting a year-on-year growth of 30.02% [1] - The company’s contract liabilities stood at 2.263 billion RMB, up 31.45% year-on-year, indicating strong future revenue support [1] Financial Performance - For the first three quarters of 2025, total revenue was 25.834 billion RMB, with net profit at 7.570 billion RMB [1] - The company approved a cash dividend of 13.50 RMB per 10 shares, totaling 1.637 billion RMB, increasing cumulative dividends to 37.336 billion RMB, six times the IPO fundraising amount [2] International Market Growth - International business grew by 11.93% in Q3, with notable performance in Europe exceeding 20% growth [1][4] - The company’s international revenue share in the life information and support segment reached 70% [3] - The medical imaging segment saw international revenue accounting for 61%, while the in vitro diagnostics segment had 37% from international sales [3] Strategic Initiatives - The company plans to issue H-shares for international listing to enhance capital strength and support globalization efforts [2] - Continuous investment in R&D, with 10.40% of revenue allocated to R&D in the first three quarters, totaling 2.686 billion RMB [5] - The company has established 12 R&D centers globally and holds over 12,513 patents, including 9,034 invention patents [5] Product Development and Innovation - New product launches in Q3 included advanced diagnostic kits and medical systems, enhancing the product portfolio [6] - The company is advancing towards a smart healthcare ecosystem, integrating AI and medical devices to improve service delivery [7] - The introduction of the "Smart Decision Support System" for perioperative care demonstrates the company's commitment to innovation [7] Market Outlook - The global medical device market is expanding, and the company aims to enhance its capabilities in "smart, streamlined, and international" strategies [8] - Focus on high-potential business development and strengthening overseas localized platforms to penetrate global high-end hospitals and laboratories [8]

Core Viewpoint - The company has reported a turning point in its performance with a slight increase in revenue and a notable growth in international business, despite a decline in net profit [1][3][4]. Financial Performance - In Q3 2025, the company achieved revenue of 9.091 billion RMB, a year-on-year increase of 1.53% and a quarter-on-quarter increase of 6.88% [1]. - The net profit attributable to shareholders was 2.501 billion RMB, a year-on-year decrease of 18.69% but a quarter-on-quarter increase of 2.50% [1]. - Operating cash flow reached 3.351 billion RMB, reflecting a year-on-year growth of 30.02% [1]. - For the first three quarters of 2025, total revenue was 25.834 billion RMB, with net profit at 7.570 billion RMB [1]. Contract Liabilities - As of the end of the reporting period, contract liabilities amounted to 2.263 billion RMB, a year-on-year increase of 31.45%, indicating strong future revenue support [1]. International Business Growth - The company's international business grew by 11.93% in Q3, with significant contributions from the European market, which saw growth exceeding 20% [1][4]. - The international revenue share in the life information and support segment reached 70% in the first three quarters [3]. - The in vitro diagnostics segment also showed strong international performance, with international revenue accounting for 37% [3]. R&D Investment - The company maintains a commitment to R&D, investing approximately 10% of its revenue, with R&D expenditure reaching 2.686 billion RMB in the first three quarters of 2025 [5]. - The company has established twelve R&D centers globally and has applied for a total of 12,513 patents [5]. Product Innovation - New product launches in Q3 included various diagnostic kits and advanced medical systems, enhancing the company's product offerings in high-end markets [6][7]. - The company has developed a smart medical ecosystem integrating devices, IT, and AI, aimed at improving healthcare delivery [7]. Strategic Direction - The company is focused on three strategic directions: digitalization, streamlining operations, and internationalization, to enhance its market position and product matrix [8].